90 / 102
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 3, May/June 2016
e8
AFRICA
ST-segment elevation myocardial infarction. Although rare,
LMWH such as enoxaparin may induce thrombocytopaenia,
which could be a life-threatening complication. Physicians
should always pay attention to complications such as
thrombocytopaenia, even when using LMWH.
References
1.
Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a
historical perspective.
Blood
2008;
112
: 2607–2616.
2.
Cuker A. Recent advances in heparin-induced thrombocytopenia.
Curr
Opin Hematol
2011;
18
: 315–322.
3.
Zwicker JI, Uhl L, Huang WY,
et al
. Thrombosis and ELISA optical
density values in hospitalized patients with heparin-induced thrombo-
cytopenia.
J Thromb Haemost
2004;
2
: 2133–2137.
4.
Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia:
diagnosis and management update.
Postgrad Med J
2007;
83
: 575–582.
5.
Yeh RW, Wiviott SD, Giugliano RP,
et al
. Effect of thrombocytopenia
on outcomes following treatment with either enoxaparin or unfraction-
ated heparin in patients presenting with acute coronary syndromes.
Am
J Cardiol
2007;
100
: 1734–1738.
6.
Crafoord C. Preliminary Report on post operative treatment with
heparin as a preventative of thrombosis.
Acta Chirurgica Scand
1936;
79
: 407–426.
7.
Natelson EA, Lynch EC, Alfrey CP,
et al
. Heparin-induced thrombocy-
topenia. An unexpected response to treatment of consumption coagu-
lopathy.
Ann Intern Med
1969;
71
: 1121–1125.
8.
Bambrah RK, Pham DC, Zaiden R, et al. Heparin-induced thrombocy-
topenia.
Clin Adv Hematol Oncol
2011;
9
: 594–599.
9.
Thachil J. Heparin induced thrombocytopenia with thrombosis: a two-
step process?
Hematology
2008;
13
; 181–182.
10. Hughes M, Hayward CP, Warkentin TE,
et al
. Morphological analysis
of microparticle generation in heparin-induced thrombocytopenia.
Blood
2000;
96
: 188–194.
11. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia
with thrombotic and hemorrhagic manifestations.
Surg Gynecol Obstet
1973;
136
: 409–416.
12. Warkentin TE, Sheppard JL, Horsewood P,
et al
. Impact of the patient
population on the risk for heparin-induced thrombocytopenia.
Blood
2000;
96
: 1703–1708.
13. Warkentin TE, Greinacher A, Koster A,
et al
. Treatment and preven-
tion of heparin-induced thrombocytopenia: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. 8th edn.
Chest
2008;
133
: 340S–380S.
14. Watson H, Davidson S, Keeling D,
et al
. Guidelines on the diagnosis and
management of heparin-induced thrombocytopenia: second edition.
Br
J Haematol
2012;
159
: 528–540.
15. Lee GM, Arepally GM. Heparin-induced thrombocytopenia.
Hematology Am Soc Hematol Educ Program
2013;
2013
: 668−674.
16. Linkins LA, Dans AL, Moores LK,
et al
. Treatment and preven-
tion of heparin-induced thrombocytopenia: antithrombotic therapy
and prevention of thrombosis, 9th edn. American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines.
Chest
2012;
141
: e495S–e530S.
17. Famularo G, Gasbarrone L, Minisola G,
et al
. Systemic bleeding in a
patient with enoxaparin-induced thrombocytopenia.
Am J Emerg Med
2009;
27
: 756. e1–2.
18. Coventry DA, Webster NR. Heparin-induced thrombocytopenia and
the health economic analysis of argatroban.
Br J Anaesth
2014;
112
:
964–967.
19. Ratuapli SK, Bobba B, Zafar H. Heparin-induced thrombocytopenia
in a patient treated with fondaparinux.
Clin Adv Hematol Oncol
2010;
8:
61–65.